Disease Burden and Clinicopathologic Spectrum of Solid Tumors - Initial Experience at a Newly Established Pet-CT Centre in Northern Pakistan

Muhammad Inam Ullah Nouman; Muhammad Omair  Riaz; Tariq  Saeed; Zafar  Amin

doi:10.51253/pafmj.v75iSUPPL-7.13032

Authors

Muhammad Inam Ullah Nouman Department of Nuclear Medicine, Armed Forces Institute of Radiology and Imaging, Rawalpindi/ National University of Medical Sciences (NUMS) Pakistan
Muhammad Omair Riaz Department of Radiology, Armed Forces Institute of Radiology and Imaging, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Tariq Saeed Department of Nuclear Medicine, Armed Forces Institute of Radiology and Imaging, Rawalpindi/ National University of Medical Sciences (NUMS) Pakistan
Zafar Amin Department of Nuclear Medicine, Armed Forces Institute of Radiology and Imaging, Rawalpindi/ National University of Medical Sciences (NUMS) Pakistan

DOI:

https://doi.org/10.51253/pafmj.v75iSUPPL-7.13032

Keywords:

F-18 FDG; PET-CT; Solid tumors; Lymphoma

Abstract

Objective: To evaluate the disease burden and clinicopathologic spectrum of solid tumors presenting at a newly established PET-CT center in Northern Pakistan for staging, restaging and response to treatment evaluation.

Study Design: Cross-sectional study.

Place and Duration of Study: Armed Forces Institute of Radiology and Imaging, Pakistan from Jul 2019 to Aug 2020.

Methodology: The study included 663 patients referred for PET-CT imaging for staging, restaging and response to treatment evaluation of various solid tumors. Data on demographic characteristics, primary tumor type and sites were collected. The type and distribution of primary solid malignancies and common clinical indications for PET-CT were analyzed.

Results: Of 663 patients, 405(61.1%) were male while 258(38.9%) were female. Majority of the patients were 45-65 years of age. PET-CT imaging was primarily performed for restaging in 265(40.0%) and initial staging in 235(35.4%) patients. Lymphoma was the most frequently diagnosed malignancy in 273(41.2%), followed by breast cancer in 70(10.6%) and lung cancer in 62(9.4%) patients.

Conclusion: PET-CT imaging enhances diagnostic precision, guiding treatment decisions in oncology. The initial experience at this new center demonstrates clinicopathologic spectrum of disease burden of various solid tumors and PET-CT imaging potential to improve cancer care in Northern Pakistan, addressing the rising regional cancer burden and supporting efficient healthcare resource utilization.

Downloads

Download data is not yet available.

References

1. Sung H, Ferlay J, Siegel RL. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71(3): 209-249. http://doi.org/10.3322/caac.21660

2. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023; 73(1): 17-48.

http://doi.org/10.3322/caac.21763

3. Wild CP, Weiderpass E, Stewart BW. World Cancer Report: Cancer Research for Cancer Prevention. IARC Publications. 2020.

4. Sullivan R, Alatise OI, Anderson BO. Global cancer surgery: delivering safe, affordable, and timely cancer surgery. Lancet Oncol 2015; 16(11): 1193-1224.

http://doi.org/10.1016/S1470-2045(15)00223-5

5. Khan HM, Ramsey S, Shankaran V. Financial toxicity in cancer care: implications for clinical care and potential practice solutions. J Clin Oncol 2023; 41(16): 3051-3058.http://doi.org/10.1200/JCO.22.01799

6. Miller KD, Nogueira L, Devasia T. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin 2022; 72(5): 409-436. http://doi.org/10.3322/caac.21731

7. Smith AF, Hall PS, Hulme CT. Cost-effectiveness analysis of PET-CT-guided management for locally advanced head and neck cancer. Eur J Cancer 2017; 85: 6-14.

http://doi.org/10.1016/j.ejca.2017.07.054

8. Rowe SP, Pomper MG. Molecular imaging in oncology: current impact and future directions. CA Cancer J Clin 2022; 72(4): 333-352. http://doi.org/10.3322/caac.21713

9. Greenspan BS. Role of PET/CT for precision medicine in lung cancer: perspective of the Society of Nuclear Medicine and Molecular Imaging. Transl Lung Cancer Res 2017; 6(6): 617-620.

http://doi.org/10.21037/tlcr.2017.09.01

10. Vijayakumar S, Yang J, Nittala MR. Changing role of PET/CT in cancer care with a focus on radiotherapy. Cureus 2022; 14(12): e32840. http://doi.org/10.7759/cureus.32840

11. Salem AE, Shah HR, Covington MF. PET-CT in clinical adult oncology: I. hematologic malignancies. Cancers 2022; 14(23): 5941. http://doi.org/10.3390/cancers14235941

12. Treglia G, Pascale M, Lazzeri E. Diagnostic performance of 18F-FDG PET/CT in patients with spinal infection: a systematic review and a bivariate meta-analysis. Eur J Nucl Med Mol Imaging 2020; 47(5): 1287-1301.

http://doi.org/10.1007/s00259-019-04571-6

13. Santo G, Miceli A, Lazzarato A. Clinicians’ perspectives on PET/CT in oncological patients: an Italian National Survey. Clin Transl Imaging 2024; 12: 99–107.

http://doi.org/10.1007/s40336-023-00591-3

14. Reinert CP, Sekler J, la Fougère C, et al. Impact of PET/CT on clinical management in patients with cancer of unknown primary: a PET/CT registry study. Eur Radiol 2020; 30(3): 1325-1333. http://doi.org/10.1007/s00330-019-06518-9

15. Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer 2021; 127(16): 3029-3030.

http://doi.org/10.1002/cncr.33587

16. Li C, Lei S, Ding L. Global burden and trends of lung cancer incidence and mortality. Chin Med J 2023; 136(13): 1583-1590.

http://doi.org/10.1097/CM9.0000000000002529

17. Morton LM, Wang SS, Devesa SS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107(1): 265-276. http://doi.org/10.1182/blood-2005-06-2508

18. Hsu YC, Tsai MH, Wu G. Role of Epstein-Barr virus in breast cancer: correlation with clinical outcome and survival analysis. J Cancer 2024; 15(8): 2403-2411.

http://doi.org/10.7150/jca.93631

19. Barrington SF, Mikhaeel NG, Kostakoglu L. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014; 32(27): 3048-3058.

http://doi.org/10.1200/JCO.2013.53.5229

20. Sung H, Ferlay J, Siegel RL. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71(3): 209-249. http://doi.org/10.3322/caac.21660

21. Burguin A, Diorio C, Durocher F. Breast cancer treatments: updates and new challenges. J Pers Med 2021; 11(8): 808.

http://doi.org/10.3390/jpm11080808

22. Ramaswamy A. Lung cancer screening: review and 2021 update. Curr Pulmonol Rep 2022; 11(1): 15-28.

http://doi.org/10.1007/s13665-021-00283-1

23. Paydary K, Seraj SM, Zadeh MZ. The evolving role of FDG-PET/CT in the diagnosis, staging, and treatment of breast cancer. Mol Imaging Biol. 2019; 21(1): 1-10.

http://doi.org/10.1007/s11307-018-1181-3

24. Ming Y, Wu N, Qian T. Progress and future trends in PET/CT and PET/MRI molecular imaging approaches for breast cancer. Front Oncol 2020; 10: 1301.

http://doi.org/10.3389/fonc.2020.01301

25. Saif MW, Tzannou I, Makrilia N, Syrigos K. Role and cost-effectiveness of PET/CT in management of patients with cancer. Yale J Biol Med 2010; 83(2): 53-65.